Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

In subjects with cervical injuries, the interim efficacy data also suggest that the response rate observed is dose-dependent at the doses up to 6 mg.

To date, the safety and tolerability data for dose levels up to 6 mg indicate that Cethrin appears to be safe and well tolerated. There have been no serious adverse events related to Cethrin as determined by the investigators and the independent Data Safety Monitoring Board, or DSMB. There were two deaths of subjects enrolled in the trial. The DSMB and the clinical investigators attributed the two deaths to causes related to the subjects' initial Spinal Cord Injury, other injuries, or preexisting conditions and not related to Cethrin.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is A
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... ... 01, 2015 , ... Discovia, a leading global provider of ... has hired Scott Sanderson, an experienced business development professional and former NFL offensive ... for establishing and managing new client relationships in the Southeast U.S. He ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Brent Nelson, D.O., has joined its medical management team as an Associate Medical ... of all sizes and types in the U.S. and abroad. , Dr. ...
(Date:9/1/2015)... ... ... SC&H Group, a leading audit, tax, and consulting firm, received multiple honors from ... in the U.S., as well as being ranked a Top 100 Accounting Firm. , ... exclusively on performance in specific areas of financial and operational management. SC&H Group ...
(Date:9/1/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ... Health: Helping You Be Well videos to prostate cancer awareness. Prostate cancer is the ... concise video on Mercy Health’s YouTube channel, Mercy Health experts address issues, such as:, ...
(Date:9/1/2015)... ... 01, 2015 , ... USA Medical Card, a leading distributor ... coincide with back-to-school and the start of “sick season” for many households across ... children are sick an average of 8 to 12 times each school year. ...
Breaking Medicine News(10 mins):Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2
... MINNEAPOLIS, Feb. 23 Incisive Surgical, Inc. today,announced that ... Absorbable Staple,at the Annual Meeting of the American Academy ... 23 - 25, 2009. The INSORB|25 Skin Stapler ... the skin,to close surgical incisions. The INSORB ...
... Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under ... support of Boehringer,s pharmaceutical development programs. , ... ... Dalton Pharma Services announces the renewal of its Chemistry Services ...
... community for the disabled, and people with health problems, celebrates five ... ... Canada (PRWEB) February 23, 2009 -- Disabled World, an online disability ... years of serving people with disabilities., , ,The Disabled World ...
... to discuss the newest treatment methods and research aimed at combating ... Eating Disorder Treatment of Long Beach, will be a sponsor of ... Eating Disorder Awareness Week Events , ... Long Beach, ...
... Anatomist Dr. Gunther von Hagens - creator of the ... his name - issued a clarification to French media and ... cadaver display announced in Paris, with his own BODY ... have been an anatomist for more than thirty five years, ...
... February 23 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SIX ... an FDA 510(k) clearance for its Capnostream(TM)20 ... The Integrated Pulmonary Index(TM), the ... to integrate,the real time measures and interactions ...
Cached Medicine News:Health News:Incisive Surgical to Launch New, Stronger Absorbable Skin Staple at American Academy of Orthopaedic Surgeons Meeting 2Health News:Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement 2Health News:Disability Community Humble Beginnings Lead to Great Things at Disabled World 2Health News:Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness 2Health News:Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness 3Health News:Anatomist Dr. Gunther von Hagens, Pioneer of Anatomical Exhibitions Not Affiliated With Copycat Display in Paris 2Health News:Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM) 2Health News:Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM) 3Health News:Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM) 4
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Lifestyle Gp is a ... multi-aspheric back surface. Through a ... surface curves, the LifeStyle Gp ... of add. Plus, its multi-aspheric ...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: